Catalent Pharma starts roadshow for $450 million eight-year notes

By Paul A. Harris

Portland, Ore., Oct. 10 – Catalent Pharma Solutions, Inc. began a roadshow on Tuesday for a $450 million offering of eight-year senior notes, according to a syndicate source.

The Rule 144A and Regulation S for life deal is expected to price on Friday.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, RBC Capital Markets LLC and BofA Merrill Lynch are the joint bookrunners.

The notes become callable after three years at par plus 50% of coupon.

The Somerset, N.J.-based provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products plans to use the proceeds to finance the acquisition of Cook Pharmica.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.